Defensin alpha 9, pseudogene (DEFA9P)

Defensin alpha 9, pseudogene (DEFA9P) is a human genomic locus classified as an alpha-defensin pseudogene, meaning it originated from duplication and mutation of functional defensin genes and has accumulated sequence disruptions that prevent it from encoding an active peptide. Defensins are cationic antimicrobial peptides with vital roles in innate immunity, host defense, and mucosal barrier function[1][3][6]. Functional alpha-defensins act by disrupting microbial membranes and modulating immune responses, but pseudogenes like DEFA9P have lost these capabilities due to disrupted coding sequences (frameshifts or stop codons)[5]. There is currently no evidence for a biological function, therapeutic relevance, or disease association for DEFA9P in humans[2][5]. Additional context: - Alpha-defensin pseudogenes are common within the defensin gene clusters in both humans and mice, reflecting duplicated evolutionary history and variable loss of function[5][7][8]. - Only functional alpha-defensins (e.g., HNP1-4 in neutrophils, HD5/HD6 in Paneth cells) are active in disease and immunological roles[1][3]. - Nomenclature around defensin pseudogenes is sometimes inconsistent due to segmental duplications and genomic complexity[8]. To summarize: DEFA9P/Defensin alpha 9, pseudogene is a non-functional genomic pseudogene, not a receptor, enzyme, or therapeutic target. Its inclusion as a drug target or biomarker is incorrect for any application based on current evidence[2][5].

Other names

DEFAP2DEFA9P